title: First-line therapy with temozolomide induces regression of primary CNS lymphoma.
authors.affiliation: Department of Neurology, University of Tuebingen, Germany. ulrich.herrlinger@uni-tuebingen.de
authors.forename: U
authors.initials: U
authors.lastname: Herrlinger
authors.forename: W
authors.initials: W
authors.lastname: Küker
authors.forename: M
authors.initials: M
authors.lastname: Platten
authors.forename: J
authors.initials: J
authors.lastname: Dichgans
authors.forename: M
authors.initials: M
authors.lastname: Weller
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide